Home' Australian Pharmacist : Australian Pharmacist Oct 2013 Contents Australian Pharmacist October 2013 I © Pharmaceutical Society of Australia Ltd.
EVIDENCE IN PATIENT CARE
Submit your answers online before
1 December 2013 at www.psa.org.au
and receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Between 2000 and 2011 there was
an increase in the dispensing of
antidepressants in the order of:
2. Which of the following classes of
antidepressant are most popular in
3. Which of the following treatment
options is first-line for mild MDD?
a) An SSRI
b) An SNRI
c) Psychological therapy
d) All of the above
4. Which of the following
antidepressants is likely to be least
effective for the treatment of MDD?
5. Which of the following
antidepressants is associated
with the highest rate of sexual
1. Australian Institute of Health and Welfare. General practice
activity in Australia 2010-11. 2011.
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and
age-of-onset distributions of DSM-IV disorders in the National
Comorbidity Survey Replication. Arch Gen Psychiatry 2005;
3. Therapeutic Guidelines Ltd. Therapeutic Guidelines:
4. Hollingworth SA, Burgess PM, Whiteford HA. Affective and
anxiety disorders: prevalence, treatment and antidepressant
medication use. Aust N Z J Psychiatry 2010; 44:513-9 .
5. Stephenson CP, Karanges E, McGregor IS. Trends in the
utilisation of psychotropic medications in Australia from 2000
to 2011. Aust N Z J Psychiatry 2013; 47:74-87.
6. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of
psychotherapy for adult depression are overestimated: a
meta-analysis of study quality and effect size. Psychol Med
7. Bortolotti B, Menchetti M, Bellini F, et al. Psychological
interventions for major depression in primary care: a meta-
analytic review of randomized controlled trials. Gen Hosp
Psychiatry 2008; 30:293-302.
8. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs
for mental disorders in England, 1998-2010. Br J Psychiatry : the
journal of mental science 2012; 200:393-8 .
9. Olfson M, Marcus SC. National patterns in antidepressant
medication treatment. Arch Gen Psychiatry 2009; 66:848-56.
10. Munoz-Arroyo R, Sutton M, Morrison J. Exploring potential
explanations for the increase in antidepressant prescribing in
Scotland using secondary analyses of routine data. Br J Gen
Pract: the journal of the Royal College of General Practitioners
11. Moore M, Yuen HM, Dunn N, et al. Explaining the rise in
antidepressant prescribing: a descriptive study using the
general practice research database. BMJ 2009; 339:b3999.
12. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in
primary care: a meta-analysis. Lancet 2009; 374:609-19.
13. Cameron IM, Lawton K, Reid IC. Appropriateness of
antidepressant prescribing: an observational study in a Scottish
primary-care setting. Br J Gen Pract : the journal of the Royal
College of General Practitioners 2009; 59:644-9 .
14. George K, Davison TE, McCabe M, et al. Treatment of
depression in low-level residential care facilities for the elderly.
Int psychogeriatr / IPA 2007; 19:1153-60 .
15. Smith GP. For richer, for poorer, in sickness and in health: the
entanglement of science and marketing. Aust N Z J Psychiatry
16. Parker G. Is depression overdiagnosed? Yes. BMJ 2007; 335:328.
17. Spence D. Are antidepressants overprescribed? Yes. BMJ 2013;
18. Reid IC. Are antidepressants overprescribed? No. BMJ 2013;
19. Turner EH, Matthews AM, Linardatos E, et al. Selective
publication of antidepressant trials and its influence on
apparent efficacy. NEJM 2008; 358:252-60 .
20. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and
antidepressant benefits: a meta-analysis of data submitted to
the Food and Drug Administration. PLoS medicine 2008; 5:e45.
21. Zimmerman M, Posternak MA, Chelminski I. Symptom severity
and exclusion from antidepressant efficacy trials. J Clin
Psychopharmacol 2002; 22:610-4 .
22. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug
effects and depression severity: a patient-level meta-analysis.
JAMA 2010; 303:47-53.
23. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative
benefits and harms of second-generation antidepressants for
treating major depressive disorder: an updated meta-analysis.
Ann Intern Med 2011; 155:772-85.
24. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy
and acceptability of 12 new-generation antidepressants: a
multiple-treatments meta-analysis. Lancet 2009; 373:746-58.
25. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for
acute treatment of major depression: systematic review and
meta-analysis of published and unpublished placebo and
selective serotonin reuptake inhibitor controlled trials. BMJ
26. Carney RM, Shelton RC. Agomelatine for the treatment of
major depressive disorder. Expert Opin Pharmacother 2011;
27. Mottram P, Wilson K, Strobl J. Antidepressants for depressed
elderly. The Cochrane database of systematic reviews
28. Adli M, Baethge C, Heinz A, et al. Is dose escalation of
antidepressants a rational strategy after a medium-dose
treatment has failed? A systematic review. Eur Arch Psychiatry
Clin Neurosci 2005; 255:387-400.
29. Sawada N, Uchida H, Suzuki T, et al. Persistence and
compliance to antidepressant treatment in patients with
depression: a chart review. BMC Psychiatry 2009; 9:38.
30. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy
versus medication in augmentation and switch strategies as
second-step treatments: a STAR*D report. Am J Psychiatry
2007; 164:739-52 .
Links Archive Australian Pharmacist Sept 2013 Australian Pharmacist Nov 2013 Navigation Previous Page Next Page